We understand the importance that real-world evidence plays in market access success. Demonstrating the clinical and economic benefit of your product is vital to obtaining reimbursement. Our experienced team of health economists can help you with health economic modeling for submissions; publication and study development, including Observational, Willingness-to-Pay, Pay for Performance models and Burden of Illness studies; and Canadian adaptation of global economic models.

We have extensive experience building budget impact analyses (BIAs) for complex specialty products, including rare disease, oncology and immunology (including biosimilar) products; as well as medical device and diagnostics. Our BIA models are developed within established guidelines of individual public and private payers, and clearly articulate the incremental impact to the drug plan’s bottom-line.